pfizer辉瑞品牌怎么样 申请店铺

我要投票 pfizer辉瑞在中草药行业中的票数:1671 更新时间:2026-02-04
pfizer辉瑞是哪个国家的品牌?「pfizer辉瑞」是 辉瑞投资有限公司 旗下著名品牌。该品牌发源于上海,由创始人苗天祥在1998期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力pfizer辉瑞品牌出海!将品牌入驻外推网,定制pfizer辉瑞品牌推广信息,可以显著提高pfizer辉瑞产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

pfizer辉瑞怎么样

辉瑞公司创建于1849年,迄今已有160多年的历史,总部位于美国纽约,是目前全球最大的以研发为基础的生物制药公司之一。

辉瑞生物制药在华上市的创新药物已超过50个,其治疗领域涵盖了心脑血管及代谢、抗感染、中枢神经、抗炎镇痛、抗肿瘤、泌尿、血液健康(包括血友病)等诸多领域。其中如立普妥®、络活喜®、万艾可®、舒普深®、大扶康®、希舒美®、索坦®、开普拓®、阿诺新®、任捷®、贝赋®等许多产品在市场上处于领先地位。为了让中国的广大患者能及时接受与全球同步的先进的药物治疗,辉瑞未来将进一步加大和加快在华新药引进和上市的力度和速度。

辉瑞健康药物旗下的善存®、钙尔奇®、惠菲宁®等消费保健产品也在中国市场家喻户晓,并以其优异的品质深受广大消费者的青睐。

自20世纪80年代进入中国以来,辉瑞目前已发展成为在华大型外资制药企业。辉瑞在中国有约10000多名员工,业务覆盖了全国250余个城市。辉瑞始终把“携手共创健康中国”作为在华的使命,承诺并积极参与促进中国医疗卫生事业的发展和提高人民健康水平。我们志在通过创新的、富有社会责任并且商业可行的方式,满足中国13亿人民多样化的医疗服务需求。除了提供广泛的创新医药健康产品组合外,辉瑞还积极与有关政府部门、科研/医疗机构、学术组织、社会团体等各方面合作,通过开展患者教育、疾病宣传、健康管理、社区医疗、人才培养等项目积极推动中国医疗卫生事业的发展。

Founded in 1849, Pfizer has a history of more than 160 years. Headquartered in New York, the company is one of the largest R & D-based biopharmaceutical companies in the world. Pfizer biopharmaceuticals has been listed in more than 50 innovative drugs in China, and its treatment fields cover cardio cerebrovascular and metabolism, anti infection, central nervous system, anti-inflammatory and analgesic, anti-tumor, urinary, blood health (including hemophilia) and many other fields. Among them, many products, such as Lipitor ®, luohuoxi ®, Viacom ®, shupushen ®, Dafukang ®, sisumi ®, sotan ®, keputuo ®, anoxin ®, Renjie ®, Beifu ®, are in the leading position in the market. In order to enable the vast number of patients in China to receive advanced drug treatment in time with the global synchronization, Pfizer will further increase and speed up the introduction and marketing of new drugs in China in the future. Pfizer's consumer health care products, such as Shancun ®, Caltech ®, and huifeining ®, are also well known in the Chinese market, and are favored by the majority of consumers with their excellent quality. Since entering China in 1980s, Pfizer has developed into a large foreign pharmaceutical enterprise in China. Pfizer has more than 10000 employees in China, covering more than 250 cities across the country. Pfizer has always taken "working together to create a healthy China" as its mission in China, committed to and actively participated in promoting the development of China's medical and health undertakings and improving the people's health level. We aim to meet the diverse needs of China's 1.3 billion people through innovative, socially responsible and commercially viable ways. In addition to providing a wide range of innovative pharmaceutical and health product portfolio, Pfizer also actively cooperates with relevant government departments, scientific research / medical institutions, academic organizations, social organizations and other aspects, and actively promotes the development of China's medical and health undertakings through patient education, disease publicity, health management, community medical care, talent training and other projects.

本文链接: https://brand.waitui.com/9f250b20b.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

重庆啤酒:2025年度归母净利润12.31亿元,同比增长10.43%

36氪获悉,重庆啤酒发布2025年业绩快报。报告显示,公司报告期内实现营业总收入147.22亿元,同比增长0.53%;归属于上市公司股东的净利润12.31亿元,同比增长10.43%;基本每股收益2.54元。

2小时前

土耳其反垄断监管机构对谷歌启动调查

土耳其竞争委员会2月4日宣布对谷歌展开新一轮反垄断调查。尽管此前谷歌已因安卓系统相关协议受罚并调整政策,但调查发现其通过财务激励引导厂商签署可选协议,实际上仍实现了搜索组件和浏览器的预装及默认地位。此外,委员会还将审查其防止开发分叉系统的限制性条款及开发者验证程序。此举旨在评估谷歌是否通过新合同结构继续规避监管并损害移动市场竞争。(财联社)

2小时前

中谷物流:拟投资建造2艘6000TEU集装箱船舶 合同总金额不超11.6亿人民币

36氪获悉,中谷物流公告,公司或其子公司拟与招商局金陵船舶(江苏)有限公司签订2艘6,000TEU集装箱船舶建造合同,合同总金额不超过11.6亿人民币或等值美元(不含税)。本次投资旨在打造经济性高、竞争力强的集装箱运输船队,不断提升企业竞争力,增强公司盈利能力和可持续发展能力。本次交易不构成关联交易,不构成重大资产重组,且无需提交股东会审议。但本次交易具体实施可能涉及境外投资事项,尚需在国家相关部门备案。

2小时前

多家中小银行宣布上调存款利率

随着春节脚步临近,多地中小银行近期宣布上调存款利率,例如湖南新晃农商行、陕西镇巴农商行、山西临县农商行等,均在1月下旬将部分期限存款利率上浮。不仅如此,部分银行还推出“限时专享”的新年专属存款产品。不过,利率上调并非统一趋势,在市场利率下行的背景下,亦有部分银行近期选择下调各期限存款利率。有业内人士指出,考虑到净息差处于低位并且仍然有下行压力,银行需要降低负债成本稳定净息差等因素,未来存款利率大概率稳定在低位或者有小幅下调。(每经网)

2小时前

松下新设首席人工智能官

松下2月4日宣布高管架构调整,新设解决方案营收官(SRO)职位,负责统筹跨领域举措以优化被列为优先领域的解决方案领域的盈利结构;同时设立首席人工智能官(CAIO)职位,推动加速运用人工智能解决客户问题并提升内部运营效率。新设职位将于4月1日生效。公告显示,Hirofumi Suzuki被任命为解决方案营收官,Akira Sakakibara被任命为首席人工智能官。(界面)

2小时前

本页详细列出关于pfizer辉瑞的品牌信息,含品牌所属公司介绍,pfizer辉瑞所处行业的品牌地位及优势。
咨询